These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 35883678)
21. New Means and Challenges in the Targeting of BTK. Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606 [TBL] [Abstract][Full Text] [Related]
23. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor. Kriegsmann K; Kriegsmann M; Witzens-Harig M Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636 [TBL] [Abstract][Full Text] [Related]
24. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
26. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227 [TBL] [Abstract][Full Text] [Related]
27. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells. Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728 [TBL] [Abstract][Full Text] [Related]
28. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337 [TBL] [Abstract][Full Text] [Related]
29. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722 [TBL] [Abstract][Full Text] [Related]
30. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. Till KJ; Pettitt AR; Slupsky JR J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006 [TBL] [Abstract][Full Text] [Related]
31. Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. Chen SS; Chiorazzi N Hematol Oncol; 2023 Jun; 41 Suppl 1():119-128. PubMed ID: 37294973 [TBL] [Abstract][Full Text] [Related]
34. Targeting Bruton's Tyrosine Kinase in CLL. Ahn IE; Brown JR Front Immunol; 2021; 12():687458. PubMed ID: 34248972 [TBL] [Abstract][Full Text] [Related]
35. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. Spaargaren M; de Rooij MF; Kater AP; Eldering E Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503 [TBL] [Abstract][Full Text] [Related]
37. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia. Rhodes JM; Mato AR Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166 [TBL] [Abstract][Full Text] [Related]
38. SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Easaw S; Ezzati S; Coombs CC Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):697-704. PubMed ID: 37544810 [TBL] [Abstract][Full Text] [Related]
39. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427 [TBL] [Abstract][Full Text] [Related]
40. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]